T. Rowe Price Associates
CERE

T. Rowe Price Associates’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

T. Rowe Price Associates’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-53,401
Closed -$2.18M – 3047
2024
Q2 		$2.18M Sell
53,401
-281,956
-84% -$11.7M ﹤0.01% 1516
2024
Q1 		$14.2M Sell
335,357
-385,698
-53% -$16.2M ﹤0.01% 1053
2023
Q4 		$30.6M Sell
721,055
-4,782,443
-87% -$137M ﹤0.01% 844
2023
Q3 		$120M Buy
5,503,498
+278,698
+5% +$6.97M 0.02% 482
2023
Q2 		$166M Buy
5,224,800
+425,093
+9% +$13M 0.02% 426
2023
Q1 		$117M Sell
4,799,707
-4,887
-0.1% -$143K 0.02% 481
2022
Q4 		$152M Buy
4,804,594
+35,520
+0.7% +$1M 0.02% 426
2022
Q3 		$135M Sell
4,769,074
-1,526,834
-24% -$45.5M 0.02% 434
2022
Q2 		$166M Sell
6,295,908
-182,102
-3% -$5.17M 0.02% 523
2022
Q1 		$227M Buy
6,478,010
+477,088
+8% +$13.9M 0.02% 491
2021
Q4 		$195M Buy
6,000,922
+160,191
+3% +$5.65M 0.02% 562
2021
Q3 		$172M Buy
5,840,731
+2,513,320
+76% +$70.6M 0.02% 593
2021
Q2 		$85.2M Sell
3,327,411
-72,477
-2% -$1.04M 0.01% 844
2021
Q1 		$46.7M Buy
3,399,888
+7,755
+0.2% +$113K ﹤0.01% 1028
2020
Q4 		$54M Buy
+3,392,133
New +$44.1M 0.01% 936

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

T. Rowe Price Associates's CERE Position: Q3 2024 in Review

T. Rowe Price Associates sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 53,401 shares — an estimated $2.18M sold.

T. Rowe Price Associates first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $227M in Q1 2022. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • T. Rowe Price Associates reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 53,401 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $2.18M.
  • T. Rowe Price Associates first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • T. Rowe Price Associates's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $227M in Q1 2022.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on T. Rowe Price Associates's 13F filing for Q3 2024, filed 14 Nov 2024.